Clinical and Pathological Features of Lipid Storage Myopathy; A Retrospective Study of a Large Group from Iran
International Clinical Neuroscience Journal,
Vol. 8 No. 1 (2021),
30 December 2020
Background: Lipid storage myopathies (LSMs) are rare diseases. The phenotype and genotype of lipid metabolism disorders are heterogeneous and divided into two major groups. Constant or progressive proximal and axial muscle weakness associated with or without metabolic crisis, is often seen in patients with LSM such as primary carnitin deficiency (PCD) or multiple acyl-coenzyme a dehydrogenase deficiency disorder (MADD). On the other hand, rhabdomyolysis triggered by fasting, fever, or physical activity usually occurs in patients with disorders affecting intramitochondrial fatty acid transport and β-oxidation, such as carnitine palmitoyltransferase II deficiency (CPT2), mitochondrial trifunctional protein deficiency and very-long-chain acyl-CoA dehydrogenase deficiency (VLCAD).
Methods: In this cross-sectional study, we summarized the clinical profiles and muscle histology of 64 Iranian patients diagnosed with LSM by muscle biopsy. These patients were selected from 3000 patients referred for muscle biopsy to Toos and Mofid children’s hospitals during 2010 to 2016. Their affected siblings were also added to the study.
Result: In our study 45.3% of the patients were men and 54.7% were women. Mean age of the patients was 27.05 years (SD: 14.26) and the mean age of onset of symptoms in these patients was 20.94 (SD: 14.25) years. Most patients (70.3%) had proximal weakness and no bulbar involvement. Only 9.3% of the patients had a positive family history.
Conclusion: LSMs are not incommon in Iran and their phenotype can mimic inflammatory myopathy or limb girdle muscular dystrophy. Overall the demographic and clinical features of LSMs in Iranian patients were similar to prior reports.
- lipid storage myopathy
- Muscle biopsy
How to Cite
2. Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Molecular aspects of medicine. 2004;25(5-6):495-520.
3. Tobon A. Metabolic myopathies. Continuum (Minneapolis, Minn). 2013;19(6 Muscle Disease):1571-97.
4. Nilipour Y, Fatehi F, Sanatinia S, Bradshaw A, Duff J, Lochmüller H, et al. Multiple acyl-coenzyme A dehydrogenase deficiency shows a possible founder effect and is the most frequent cause of lipid storage myopathy in Iran. Journal of the neurological sciences. 2020;411:116707.
5. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. The New England journal of medicine. 2009;360(8):838-40.
6. Bonnefont JP, Bastin J, Laforêt P, Aubey F, Mogenet A, Romano S, et al. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clinical pharmacology and therapeutics. 2010;88(1):101-8.
7. Strauss AW, Powell CK, Hale DE, Anderson MM, Ahuja A, Brackett JC, et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(23):10496-500.
8. Koizumi A, Nozaki J, Ohura T, Kayo T, Wada Y, Nezu J, et al. Genetic epidemiology of the carnitine transporter OCTN2 gene in a Japanese population and phenotypic characterization in Japanese pedigrees with primary systemic carnitine deficiency. Human molecular genetics. 1999;8(12):2247-54.
9. Ramakrishnan S, Narayanappa G, Christopher R. Lipid storage myopathy with clinical markers of Marfan syndrome: A rare association. Annals of Indian Academy of Neurology. 2012;15(4):332-5.
10. Igal RA, Rhoads JM, Coleman RA. Neutral lipid storage disease with fatty liver and cholestasis. Journal of pediatric gastroenterology and nutrition. 1997;25(5):541-7.
11. Liang WC, Nishino I. State of the art in muscle lipid diseases. Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology. 2010;29(2):351-6.
12. Gayathri N VA, Das S, et al. . Metabolic disorders presenting as vacuolar myopathy. Ann Ind Acad Neurol. 1999; 2:153–60.
13. Uppin MS, Sundaram C, Meena AK, Reddy KM, Reddy KK, Vanniarajan A, et al. Lipid storage myopathies with unusual clinical manifestations. Neurology India. 2008;56(3):391-3.
14. Ohkuma A, Noguchi S, Sugie H, Malicdan MC, Fukuda T, Shimazu K, et al. Clinical and genetic analysis of lipid storage myopathies. Muscle & nerve. 2009;39(3):333-42.
15. Tavian D, Missaglia S, Redaelli C, Pennisi EM, Invernici G, Wessalowski R, et al. Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function. Human molecular genetics. 2012;21(24):5318-28.
16. Di Mauro S, Trevisan C, Hays A. Disorders of lipid metabolism in muscle. Muscle & nerve. 1980;3(5):369-88.
17. Rebouche CJ, Engel AG. Carnitine metabolism and deficiency syndromes. Mayo Clinic proceedings. 1983;58(8):533-40.
- Abstract Viewed: 251 times
- PDF Downloaded: 224 times